Navya Konindala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Navya Konindala has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Mayer
Critical Care Medicine , Memorial Hospital West , Pembroke Pines , Florida , USA
1 shared publication - Hima Darapu
Department of Endocrinology, Atrium Health Wake Forest Baptist Medical Center , Winston-Salem, NC 27157
1 shared publication - Myeongji Kim
Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA
1 shared publication - Ravi Kumar Paluri
Department of Hematology and Medical Oncology, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC 27157, USA
1 shared publication
Latest Publications
- Open Access
- 3 December 2025
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (1)
Aggressive Macroprolactinoma Refractory to Multiple Lines of Localized and Systemic Therapy
Aggressive prolactinomas are rare and pose considerable therapeutic challenges, especially in cases refractory to conventional treatments, including dopamine agonists, surgery, and radiotherapy. We present a case of a 77-year-old man with refractory, treatment-resistant macroprolactinoma and describe the sequential use of capecitabine temozolomide, olaparib bevacizumab, pembrolizumab, and pazopanib. Despite disease progression on multiple lines of therapy, pazopanib achieved disease stability, after which the tumor demonstrated slow progression. This case highlights the urgent need for novel therapeutic approaches and predictive biomarkers in managing refractory aggressive prolactinomas.
- 3 December 2025
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (1)
Open AccessAggressive Macroprolactinoma Refractory to Multiple Lines of Localized and Systemic Therapy
Aggressive prolactinomas are rare and pose considerable therapeutic challenges, especially in cases refractory to conventional treatments, including dopamine agonists, surgery, and radiotherapy. We present a case of a 77-year-old man with refractory, treatment-resistant macroprolactinoma and describe the sequential use of capecitabine temozolomide, olaparib bevacizumab, pembrolizumab, and pazopanib. Despite disease progression on multiple lines of therapy, pazopanib achieved disease stability, after which the tumor demonstrated slow progression. This case highlights the urgent need for novel therapeutic approaches and predictive biomarkers in managing refractory aggressive prolactinomas.
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Endocrine Surgery
- Vol. 23 (2) , 59-63
A Case Report of Severe Tracheal Compression Secondary to a Large Benign Substernal Goiter
Kim M, et al. J Endocr Surg. 2023 Jun;23(2):59-63. https://doi.org/10.16956/jes.2023.23.2.59
- 1 January 2023
- Published by XMLink in Journal of Endocrine Surgery
- Vol. 23 (2) , 59-63
Open AccessA Case Report of Severe Tracheal Compression Secondary to a Large Benign Substernal Goiter
Kim M, et al. J Endocr Surg. 2023 Jun;23(2):59-63. https://doi.org/10.16956/jes.2023.23.2.59